Neurogene Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $19.52 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $17.77, a 9.69% increase year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $16.20, a 53.17% decline year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $34.59, a 5762.71% increase year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.59, a 76.02% decline year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $17.13, a 52.19% decline from fiscal 2024.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $35.83, a 89.48% increase from fiscal 2023.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $18.91, a 1332.58% increase from fiscal 2022.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.32, a 84.83% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 0 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19.52 10-Q · filed 2026-08-11 | |||||
| 2026-03-31 | $17.77 10-Q · filed 2026-05-12 | |||||
| 2025-12-31 | $17.13 10-K · filed 2026-03-24 | |||||
| 2025-09-30 | $17.09 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | $16.77 10-Q · filed 2025-08-11 | |||||
| 2025-03-31 | $16.20 10-Q · filed 2025-05-09 | |||||
| 2024-12-31 | $35.83 10-K · filed 2025-03-24 | |||||
| 2024-09-30 | $35.31 10-Q · filed 2024-11-18 | |||||
| 2024-06-30 | $34.96 10-Q · filed 2024-08-09 | |||||
| 2024-03-31 | $34.59 10-Q · filed 2024-05-10 | |||||
| 2023-12-31 | $18.91 10-K · filed 2024-03-18 | |||||
| 2023-09-30 | $3.52 10-Q · filed 2023-11-14 | |||||
| 2023-06-30 | $0.70 10-Q · filed 2023-08-10 | |||||
| 2023-03-31 | $0.59 10-Q · filed 2023-05-08 | |||||
| 2022-12-31 | $1.32 10-K · filed 2023-03-20 | |||||
| 2022-09-30 | $1.34 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | $2.06 10-Q · filed 2022-08-09 | |||||
| 2022-03-31 | $2.46 10-Q · filed 2022-05-09 | |||||
| 2021-12-31 | $8.70 10-K · filed 2022-03-01 | |||||
| 2021-09-30 | $8.85 10-Q · filed 2021-11-04 | |||||
| 2021-06-30 | $12.29 10-Q · filed 2021-08-05 | |||||
| 2021-03-31 | $12.83 10-Q · filed 2021-05-12 | |||||
| 2020-12-31 | $11.60 10-K · filed 2021-03-25 | |||||
| 2020-09-30 | $11.52 10-Q · filed 2020-11-09 | |||||
| 2020-06-30 | $10.58 10-Q · filed 2020-08-12 | |||||
| 2020-03-31 | $7.63 10-Q · filed 2020-05-06 | |||||
| 2019-12-31 | $2.91 10-K · filed 2020-03-12 | |||||
| 2019-09-30 | $3.54 10-Q · filed 2019-11-13 | |||||
| 2018-12-31 | $9.09 10-K · filed 2019-03-07 | |||||
| 2018-09-30 | $9.10 10-Q · filed 2018-11-07 | |||||
| 2018-06-30 | $15.92 10-Q · filed 2018-08-08 | |||||
| 2018-03-31 | $16.55 10-Q · filed 2018-05-08 | |||||
| 2017-12-31 | $16.63 10-K · filed 2018-03-12 | |||||
| 2017-09-30 | $16.92 10-Q · filed 2017-11-08 | |||||
| 2017-06-30 | $16.97 10-Q · filed 2017-08-08 | |||||
| 2017-03-31 | $17.35 10-Q · filed 2017-05-09 | |||||
| 2016-12-31 | $8.77 10-K · filed 2017-03-09 | |||||
| 2016-09-30 | $8.33 10-Q · filed 2016-11-09 | |||||
| 2016-06-30 | $8.19 10-Q · filed 2016-08-04 | |||||
| 2016-03-31 | $8.29 10-Q · filed 2016-05-10 | |||||
| 2015-12-31 | $11.51 10-K · filed 2016-03-14 | |||||
| 2015-09-30 | $11.46 10-Q · filed 2015-11-10 | |||||
| 2015-06-30 | $11.42 10-Q · filed 2015-08-06 | |||||
| 2015-03-31 | $11.70 10-Q · filed 2015-05-12 | |||||
| 2014-12-31 | $10.13 10-K · filed 2015-03-16 | |||||
| 2014-08-07 | $7.50 10-Q · filed 2014-11-04 | |||||
| 2014-05-08 | $10.10 10-Q · filed 2014-11-04 | $10.10 10-Q · filed 2014-08-11 | ||||
| 2013-04-08 | $5.76 10-Q · filed 2014-11-04 | |||||
| 2013-04-02 | $5.76 10-Q · filed 2014-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |